

## Original article

# Telomerase activity in patients with stage 2–5D chronic kidney disease<sup>☆</sup>

Veysel Kidir<sup>a,\*</sup>, Ayse Aynali<sup>b</sup>, Atila Altuntas<sup>a</sup>, Salih Inal<sup>a</sup>,  
Buket Aridogan<sup>b</sup>, Mehmet Tugrul Sezer<sup>a</sup>

<sup>a</sup> Division of Nephrology, Department of Internal Medicine, Suleyman Demirel University Medical Faculty, Isparta, Turkey

<sup>b</sup> Department of Medical Microbiology, Suleyman Demirel University Medical Faculty, Isparta, Turkey

## ARTICLE INFO

## Article history:

Received 14 December 2016

Accepted 18 March 2017

Available online 11 July 2017

## Keywords:

Chronic kidney disease

Stage

Telomerase

## ABSTRACT

**Background:** Molecular mechanisms of increased cardiovascular mortality in chronic kidney disease (CKD) associated with biological age are not well understood. Recent studies support the hypothesis that common factors responsible for this phenomenon are cellular aging and telomere dysfunction.

**Objectives:** The purpose of this study was to investigate the relation between telomerase activity and CKD stages.

**Methods:** The study included 120 patients who were followed-up for CKD stage 2–5D, composed of 30 patients of each stage and 30 healthy volunteers without any known disease who were admitted to our hospital for routine check-ups. Telomerase activity in peripheral blood mononuclear cells (PBMC) was measured using the TRAP assay.

**Results:** A significant difference was observed for telomerase activity in PBMC between groups. The detected levels were lowest in the healthy control group ( $0.15 \pm 0.02$ ), and highest in CKD stage 5D patients ( $0.23 \pm 0.04$ ). In CKD patients, telomerase activity in PBMC was positively correlated with the CKD stage, serum creatinine, potassium and parathormone levels, and negatively correlated with estimated glomerular filtration rate (eGFR), body mass index (BMI), platelet count and serum calcium levels. According to the linear regression analysis, independent predictors for high telomerase activity in CKD patients were eGFR and BMI.

**Conclusion:** Telomerase activity in PBMC increases with advancing CKD stage in CKD patients. Increased telomerase activity in PBMC is associated with eGFR and BMI.

© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>☆</sup> This study was presented at the ASN Kidney Week 2015, 3–8 November 2015, San Diego, USA.

\* Corresponding author.

E-mail address: [veyselkdr@gmail.com](mailto:veyselkdr@gmail.com) (V. Kidir).

<http://dx.doi.org/10.1016/j.nefro.2017.03.025>

0211-6995/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Actividad de la telomerasa en pacientes en etapas de 2-5D con enfermedad renal crónica

### R E S U M E N

#### Palabras clave:

Enfermedad renal crónica

Etapas

Telomerasa

**Antecedentes:** Los mecanismos moleculares responsables del aumento de la mortalidad cardiovascular en la enfermedad renal crónica (ERC) asociada a la edad biológica no se conocen bien. Los estudios recientes apoyan la hipótesis de que los factores comunes responsables de este fenómeno son el envejecimiento celular y la disfunción telomérica.

**Objetivos:** El objetivo de este estudio fue investigar la relación entre la actividad de la enzima telomerasa y los estadios de ERC.

**Métodos:** El estudio incluyó a 120 pacientes que fueron seguidos para la ERC en los estadios 2-5D; cada estadio incluyó a 30 pacientes y a 30 voluntarios sanos sin ninguna enfermedad conocida que fueron admitidos en nuestro hospital para los controles periódicos. La actividad de la telomerasa en células mononucleares de sangre periférica (CMSP) se midió usando el método de TRAP.

**Resultados:** Se observó una diferencia significativa en la actividad telomerasa en las CMSP entre los diferentes grupos. Los niveles más bajos fueron los del grupo de controles sanos ( $0,15 \pm 0,02$ ) y los más altos los del grupo de pacientes con ERC en el estadio 5D ( $0,23 \pm 0,04$ ). En los pacientes con ERC, la actividad telomerasa en las CMSP se correlacionó positivamente con el estadio de ERC y los niveles plasmáticos de potasio, hormona paratiroidea y creatinina, y se correlacionó negativamente con la tasa de filtración glomerular estimada (eTFG), el índice de masa corporal (IMC), el recuento de plaquetas y el calcio en suero. Los predictores independientes para la actividad telomerasa alta en pacientes con ERC fueron la eTFG y el IMC, de acuerdo con el análisis de regresión lineal.

**Conclusión:** La actividad telomerasa en CMSP aumenta con el avance en el estadio de ERC. El aumento de la actividad telomerasa en CMSP se asocia con la eTFG y el IMC.

© 2017 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Epidemiological studies have shown that biological age is older than chronologic age in chronic kidney disease (CKD) patients.<sup>1-3</sup> Molecular mechanisms of increased cardiovascular mortality in CKD associated with biological age are not well understood. Recent studies suggest that factors such as cellular aging and telomere dysfunction may be the responsible factors.<sup>4-6</sup> Studies conducted in hemodialysis patients have shown that telomere length in peripheral blood mononuclear cells (PBMC) was reduced compared to healthy individuals, irrespective of age and gender.<sup>7,8</sup> Telomerase enzyme maintains the length and structure of telomeres, thus provides longer cell survival.<sup>9,10</sup> Telomerase activity in PBMC was found significantly lower in hemodialysis patients compared to the healthy control group.<sup>11</sup>

Telomerase activity levels in various CKD stages and its relation to CKD progression are not well understood. This study was aimed to determine the relation between telomerase activity and CKD stages.

## Materials and method

### Study design and patient assignment

This study was approved by the University Clinical Research Ethics Committee with approval number 2014/35 and was

conducted with the support of Scientific Research Projects Coordination Unit. Written consent was obtained from all participants. This cross-sectional study was conducted at the Süleyman Demirel University Medical School Nephrology Department between May 2014 and November 2014. The study included 120 patients who were followed-up for CKD stage 2-5D, composed of 30 patients of each stage, and 30 healthy volunteers.

Inclusion criteria were age over 18 years and having CKD stage 2-5D diagnosis. Exclusion criteria included presence of an acute infection and a malignancy and using immunosuppressive therapy.

### Blood sampling

Complete blood count, blood levels of fasting blood glucose, serum creatinine (Cr), sodium (Na), potassium (K), calcium (Ca), phosphorus (P), albumin, alanine aminotransferase (ALT), aspartat aminotransferase (AST), uric acid, triglyceride, total cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), 25-hydroxy-vitamin D (25(OH)D), parathormone (iPTH), C-reactive protein (CRP) and spot urine protein/creatinine (Upr/Ucr) values were measured in each patient. Blood samples of hemodialysis patients were collected just before mid-week dialysis session. Body mass index (BMI) was calculated. Estimated GFR (eGFR) levels were calculated using

**Table 1 – Baseline clinical and laboratory data of CKD patients.**

	Stage 2CKD(n=30)	Stage 3CKD(n=30)	Stage 4CKD(n=30)	Stage 5DCKD(n=30)	P
Age, years	59.6 ± 9.7	59.3 ± 8.7	59.2 ± 9.6	59.6 ± 10.1	0.997
Male, n (%)	14 (47)	14 (47)	14 (47)	14 (47)	1
BMI (kg/m <sup>2</sup> )	27.8 ± 5.2	28.8 ± 5.4	28.2 ± 4.6	26.2 ± 5.6	0.268
Smoking, n (%)	3 (10)	8 (27)	2 (7)	3 (10)	0.093
eGFR (ml/dk)	65.9 ± 8.4 <sup>a,b,c</sup>	37.1 ± 6.2 <sup>a,d,e</sup>	23.1 ± 5.5 <sup>b,d,f</sup>	7.6 ± 3.2 <sup>c,e,f</sup>	<0.001
Glucose (mg/dl)	113 ± 33	118 ± 41	115 ± 39	142 ± 68	0.068
Creatinine (mg/dl)	1.03 ± 0.1 <sup>a,b</sup>	1.7 ± 0.2 <sup>c</sup>	2.6 ± 0.7 <sup>a,d</sup>	7.5 ± 3.1 <sup>b,c,d</sup>	<0.001
Sodium (mEq/l)	139 ± 2	138 ± 2	133 ± 22	136 ± 3	0.164
Potassium (mEq/l)	4.5 ± 0.5 <sup>a,b</sup>	4.8 ± 0.5	4.8 ± 0.4 <sup>a</sup>	4.9 ± 0.7 <sup>b</sup>	0.005
Calcium (mg/dl)	9.7 ± 0.5 <sup>a,b</sup>	9.6 ± 0.6 <sup>c,d</sup>	9.2 ± 0.5 <sup>a,c,e</sup>	8.5 ± 0.8 <sup>b,d,e</sup>	<0.001
Phosphorus (mg/dl)	3.7 ± 0.7 <sup>a</sup>	3.6 ± 0.7 <sup>b</sup>	4.1 ± 0.7 <sup>c</sup>	4.8 ± 1.1 <sup>a,b,c</sup>	<0.001
Uric acid (mg/dl)	6.0 ± 1.9	6.8 ± 1.6	6.4 ± 1.4	5.9 ± 1.6	0.197
Albumin (g/dl)	4.3 ± 0.3 <sup>a,b</sup>	4.3 ± 0.8 <sup>c,d</sup>	3.8 ± 0.4 <sup>a,c</sup>	3.7 ± 0.5 <sup>b,d</sup>	<0.001
ALT (U/l)	19 ± 11	19 ± 18	17 ± 10	19 ± 15	0.940
AST (U/l)	21 ± 8	22 ± 10	20 ± 10	19 ± 13	0.748
Triglyceride (mg/dl)	166 ± 68	177 ± 95	144 ± 71	171 ± 89	0.436
LDL-C (mg/dl)	124 ± 45 <sup>a</sup>	103 ± 37	96 ± 30 <sup>a</sup>	98 ± 42	0.026
HDL-C (mg/dl)	48 ± 10	44 ± 13	43 ± 12	41 ± 11	0.104
Hemoglobin (g/dl)	13.6 ± 1.8 <sup>a,b</sup>	13.5 ± 1.4 <sup>c,d</sup>	11.5 ± 1.6 <sup>a,c</sup>	11.1 ± 1.7 <sup>b,d</sup>	<0.001
WBC (× 10 <sup>3</sup> /μl)	8.1 ± 3.4	7.8 ± 1.6	7.8 ± 2.2	8.2 ± 2.2	0.877
PLT (× 10 <sup>3</sup> /μl)	245 ± 51 <sup>a</sup>	216 ± 65	232 ± 61	204 ± 56 <sup>a</sup>	0.040
CRP (mg/dl)	4.7 ± 1.7 <sup>a</sup>	4.7 ± 2.1 <sup>b</sup>	8.9 ± 7.7 <sup>a,b</sup>	6.8 ± 4.3	0.001
iPTH (pg/ml)	65 ± 46 <sup>a,b</sup>	97 ± 51	153 ± 102 <sup>a</sup>	323 ± 216 <sup>b</sup>	<0.001
25(OH)D (ng/ml)	13.5 ± 8.4	15.3 ± 9.5	9.1 ± 5.7	11.8 ± 13.4	0.084
Upr/Ucr	0.2 ± 0.2 <sup>a,b</sup>	0.8 ± 0.9 <sup>c</sup>	1.4 ± 1.2 <sup>a,d</sup>	3.4 ± 2.4 <sup>b,c,d</sup>	<0.001
Hypertension, n (%)	12 (40) <sup>a,b</sup>	19 (63)	24 (80) <sup>a</sup>	23 (77) <sup>b</sup>	0.005
DM, n (%)	7 (23)	9 (30)	7 (23)	12 (40)	0.444
CAD, n (%)	0 (0)	6 (20)	5 (17)	3 (10)	0.081
Heart failure, n (%)	0 (0)	1 (3)	3 (10)	3 (10)	0.255

CKD: chronic kidney disease; BMI: body mass index; eGFR: estimated glomerular filtration rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; WBC: white blood cell; PLT: platelet; CRP: C-reactive protein; iPTH: intact parathyroid hormone; 25(OH)D: 25-hydroxy vitamin D; Upr/Ucr: protein/creatinine ratio in spot urine; DM: diabetes mellitus; CAD: coronary artery disease. Data are indicated as mean ± standard deviation or percent. <sup>a,b,c,d,e</sup>There is a significant difference between the parameters marked with the same letter ( $p < 0.05$ ). For the comparison between groups, analysis of variance (ANOVA) or Kruskal-Wallis test was applied, and for the post hoc study Tukey HSD test was used.

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.<sup>12</sup>

### Measurement of telomerase activity in PBMC

Telomerase activity in PBMC was measured using TeloTAGGG Telomerase PCR ELISA kit (Roche Applied Science, Indianapolis, IN, USA) with telomeric repeat amplification protocol (TRAP) method.<sup>13</sup> All samples with an optical density 450 nm  $\geq 0.2$  were considered telomerase positive.<sup>14</sup>

### Statistical analysis

Data analysis was performed using SPSS for Windows 15.0 software. Results were expressed as mean ± standard deviation or percent values. Chi-square test, variance analysis (ANOVA) and Kruskal-Wallis variance analysis tests were used for group comparisons. Tukey's HSD test was used for post hoc analysis. Associations between qualitative variables were assessed by Spearman's or Pearson's correlation analysis. A multivariate linear regression model was used to estimate the independent effects of various predictors (analyzed variables were age, BMI, eGFR, platelet count, serum Ca, K, LDL-C, iPTH)

on telomerase activity. The level of statistical significance was  $p < 0.05$ .

## Results

Mean age was 58.6 ± 10.4 years in the control group and 59.4 ± 9.4 years in the patient group ( $p > 0.05$ ). Baseline characteristics of the patient groups are shown in Table 1. Patient groups were similar regarding BMI and smoking ( $p > 0.05$ ). Among the CKD stage 5D patients, 20 were on hemodialysis while 10 were on peritoneal dialysis. Mean dialysis duration for dialysis patients was 31.1 ± 29.7 (range, 4–120) months.

In CKD stage 5D patients, serum Ca (8.5 ± 0.8 mg/dl), serum albumin (3.7 ± 0.5 g/dl) and hemoglobin levels (11.1 ± 1.7 g/dl) and eGFR (7.6 ± 3.2 ml/min.) were significantly lower ( $p < 0.001$ ) while serum Cr (7.5 ± 3.1 mg/dl), serum P (4.8 ± 1.1 mg/dl), iPTH (323 ± 216 pg/ml) levels and Upr/Ucr ratio (3.4 ± 2.4) were significantly higher ( $p < 0.001$ ). Serum LDL-C levels were found highest in CKD stage 2 patients (124 ± 45 mg/dl) ( $p = 0.026$ ) (Table 1).


Comorbidity rates for CKD patients were, hypertension 64.2%, diabetes mellitus 29.2%, coronary artery disease 11.7%

**Table 2 – Group comparisons for telomerase activity positivity.**

	N	Telomerase positive cases % <sup>a</sup>	p
Control	30	3.3 (1/30)	<0.001
Stage 2 CKD	30	20 (6/30)	
Stage 3 CKD	30	43.3 (13/30)	
Stage 4 CKD	30	30 (9/30)	
Stage 5D CKD	30	86.6 (26/30)	

CKD: chronic kidney disease. Chi-square test was applied for the comparison between groups.

<sup>a</sup> Values in parentheses correspond to: no. of telomerase positive cases/total no. of cases.

**Fig. 1 – Telomerase activity in relation to CKD stage.**

and heart failure 5.8%. Hypertension was most prevalent in CKD stage 4 patients (Table 1).

#### Telomerase activity in PBMC

Telomerase activity in PBMC was positive in 86% (26/30) of CKD stage 5D patients while healthy control group was only 3% positive (1/30). Telomerase activity was increased with CKD stage (Table 2) ( $p < 0.001$ ). A significant difference was found for telomerase activity between patient and control groups ( $p < 0.001$ ) (Fig. 1). The levels were lowest in the healthy control group ( $0.15 \pm 0.02$ ) and highest in CKD stage 5 group ( $0.23 \pm 0.04$ ). Telomerase activities in PBMC were similar in CKD stages 2, 3 and 4 ( $p > 0.05$ ) while in stage 5 CKD it was significantly higher compared to the other stages ( $p < 0.05$ ). It was significantly lower in the healthy control group compared to all other groups ( $p < 0.05$ ) (Table 3).

**Table 4 – Linear regression analysis of factors associated with telomerase activity in CKD patients.**

Parameter	B	95% Confidence Interval	p	R <sup>2</sup>
eGFR	0.000	−0.001 to 0.000	0.020	0.257
BMI	−0.001	−0.003 to 0.000	0.020	

eGFR: estimated glomerular filtration rate; BMI: body mass index. Dependent variables included in the analysis were age, BMI, eGFR, platelet count, Ca, LDL-C, iPTH and K levels.

Dialysis patients were grouped according to dialysis duration (median duration 20 months); among the 30 patients dialysis duration was long (range 39–120 months) in 6 of the patients and short (range 4–38 months) in 24 of the patients. Telomerase activity in PBMC was similar in both subgroups ( $0.24 \pm 0.03$ ,  $0.23 \pm 0.03$ ;  $p > 0.05$ ).

In CKD patients, telomerase activity in PBMC was positively correlated with CKD stage ( $r = 0.412$ ,  $p < 0.001$ ) serum Cr ( $r = 0.404$ ,  $p < 0.001$ ), serum K ( $r = 0.189$ ,  $p = 0.038$ ) and iPTH levels ( $r = 0.245$ ,  $p = 0.007$ ) and; negatively correlated with BMI ( $r = -0.248$ ,  $p = 0.006$ ), eGFR ( $r = -0.407$ ,  $p < 0.001$ ), platelet count ( $r = -0.252$ ,  $p = 0.006$ ), LDL-C ( $r = -0.243$ ,  $p < 0.007$ ) and serum Ca levels ( $r = -0.357$ ,  $p < 0.001$ ). A positive correlation was found between telomerase activity and age in healthy controls ( $r = 0.623$ ,  $p < 0.001$ ).

Telomerase activity in CKD patients and dependent variables age, BMI, eGFR, platelet count, serum Ca, LDL-C, iPTH and K levels were evaluated by linear regression analysis. Only eGFR and BMI were found to be independent predictors for high telomerase activity ( $R^2 = 0.257$ ,  $\beta = 0.001$  for eGFR, CI = −0.001 to 0.000,  $p = 0.020$ ;  $\beta = -0.001$  for BMI, CI = −0.003 to 0.000,  $p = 0.020$ ) (Table 4).

#### Discussion

To our knowledge, unlike the previous studies, the current study is the first to report increased telomerase activity in PBMC in CKD patients. In this study, telomerase activity in PBMC was found significantly increased in CKD patients compared to healthy controls. This increase was found independent of age, gender, inflammation, hyperlipidemia and hyperparathyroidism but it was correlated with eGFR and BMI.

Telomere length was reported to decrease independent of age and gender in hemodialysis patients.<sup>7,8</sup> In renal cells of cats with CKD, increased cellular aging and short telomeres

**Table 3 – Group comparisons for telomerase activity.**

	Control (n = 30)	Stage 2 CKD (n = 30)	Stage 3 CKD (n = 30)	Stage 4 CKD (n = 30)	Stage 5D CKD (n = 30)	p
Telomerase activity	0.15 ± 0.02 <sup>a,b,c,d</sup>	0.17 ± 0.03 <sup>a,e</sup>	0.18 ± 0.03 <sup>b,f</sup>	0.18 ± 0.04 <sup>c,g</sup>	0.23 ± 0.04 <sup>d,e,f,g</sup>	<0.001

CKD: chronic kidney disease. <sup>a,b,c,d,e,f,g</sup>Data are indicated as mean ± standard deviation. There is a significant difference between the parameters marked with the same letter ( $p < 0.05$ ). For the comparison between groups, analysis of variance (ANOVA) was applied, and for the post hoc study Tukey HSD test was used.

were detected accompanied by normal telomerase activity.<sup>15</sup> Tsirpanlis et al. reported that telomerase activity in PBMC was lower in hemodialysis patients compared to the healthy control group.<sup>11</sup> In contrast with this study, telomerase activity in PBMC was found increased in our study. Despite being an unexpected result, higher prevalence of diabetes in CKD stage 5D patients in our study might be the reason for high detected telomerase activity considering high telomerase activity reported in patients with metabolic syndrome in previous studies.<sup>16</sup> Additionally, insignificantly lower BMI in CKD stage 5D patients might have contributed to the detected high telomerase activity in this subgroup. Thus, previous studies have reported that obesity associated with telomere shortening.<sup>17-19</sup>

Telomerase activity was reported to decrease with age.<sup>20</sup> Although no correlation was found between age and telomerase activity in CKD patients, a positive correlation was detected between age and telomerase activity in the healthy controls in our study. This may be associated with other factors other than age that influence telomerase activity.

The combination of high telomerase activity and short telomere was suggested to be a sign of activated cell stress.<sup>21</sup> Epel et al. in their study on caregivers of dementia patients found increased telomerase activity in PBMC accompanied by increased serum cortisol levels related to acute psychological stress.<sup>22</sup> Lack of acute stress and serum cortisol levels assessments is a limitation of this study. Further studies may clarify this issue.

Telomerase activity in PBMC was reported to be potentially associated with inflammation.<sup>23</sup> In cell cultures, increased telomerase activity in macrophages was shown in response to inflammatory stimulants.<sup>24</sup> In the study by Rentoukas et al. telomerase activity in PBMC, IL6, TNF $\alpha$  and asymmetric dimethylarginine (ADMA) levels were found significantly higher in metabolic syndrome patients compared to healthy controls. Additionally, a positive correlation was observed between telomerase activity and ADMA levels while no correlation was found between telomerase activity and IL6 or TNF $\alpha$ .<sup>16</sup> In this study, CRP was the only evaluated inflammatory marker. A significant relation was not found between telomerase activity in PBMC and CRP. However, this result may be due to the fact that this study excluded patients with acute infection.

Lin et al. measured telomerase activity and telomere length in various subtypes of T and B cells (CD4+, CD8+ CD28+ and CD8+ CD28- T and B cells). They found the longest telomere and highest telomerase activity was in B cells, while shortest telomere and lowest telomerase activity was in CD8+ CD28- cells.<sup>25</sup> In patients with unstable angina, telomerase activity in polymorphonuclear neutrophils in atherosclerotic plaques was found significantly higher compared to circulating neutrophils and this was suggested to be related to activation of inflammatory cells in early stage of instability and their locally prolonged survival.<sup>26</sup> In our study, telomerase activity assessment in T and B subtypes was lacking since subtype analysis for PBMC was not performed. However, accelerated atherosclerosis and chronic micro-inflammation can be speculated as contributing factors to the findings in this study. Further studies will set light to this issue.

Obesity was reported to accelerate cellular aging and was found associated with telomere shortening.<sup>17-19</sup> In our study, high BMI was associated with low telomerase activity in CKD patients. Telomerase activity levels were lower in obese patients. This result supports the previous observations suggesting obesity is related with telomere shortening in CKD patients.

Telomerase activity in PBMC was found negatively correlated with oxidized LDL-C.<sup>27</sup> Statin treatment was associated with high telomerase activity and long telomeres, independent from age, lipid levels and inflammation.<sup>28</sup> In our study, unlike previous studies, telomerase activity in PBMC was not associated with LDL-C. This result may be due to the fact that 1/5 of our patients were on statins.

Cross-sectional design and relatively small number of patients and controls are the other limitations of our study.

In conclusion; to our knowledge, this study is important for being the first to evaluate the relation between CKD stages and telomerase activity in PBMC. Based on the results of our study, it can be concluded that telomerase activity in PBMC is increased in CKD patients compared to healthy individuals. Telomerase activity in PBMC is increased with advancing stage in CKD patients and particularly in end-stage renal failure. Confirmation of this result in further studies may open new horizons in prevention of biological aging.

---

## Author contributions

Concept – V.K.; design – V.K., A.Y.A.; supervision – M.T.S., B.A.; resource – V.K., A.Y.A.; materials – V.K., A.Y.A.; data collection and/or processing – V.K., A.Y.A., A.T.A., S.I.; analysis and/or interpretation – V.K., S.I.; literature search – V.K.; writing – V.K.; critical reviews – M.T.S.

---

## Conflict of interest

The authors declare that they have no conflict of interest.

---

## REFERENCES

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know?, What do we need to learn? Where do we go from here? *Am J Kidney Dis.* 1998;32:853-906.
2. Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. *Nephrol Dial Transplant.* 2001;16:459-68.
3. Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in endstage renal failure patients. *Kidney Blood Press Res.* 2005;28:55-61.
4. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. *Circ Res.* 2007;100:15-26.
5. Fuster JJ, Andres V. Telomere biology and cardiovascular disease. *Circ Res.* 2006;99:1167-80.
6. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh's dilemma. *Am J Physiol Heart Circ Physiol.* 2006;290:1729-39.

7. Ramírez R, Carracedo J, Soriano S, Jiménez R, Martín-Malo A, Rodríguez M, et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. *Am J Kidney Dis.* 2005;45:353-9.
8. Borrás M, Panizo S, Sarró F, Valdivielso JM, Fernández E. Assessment of the potential role of active vitamin D treatment in telomere length: a case-control study in hemodialysis patients. *Clin Ther.* 2012; 34:849-56.
9. BenPorath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. *J Clin Invest.* 2004;113:8-13.
10. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. *FEBS Lett.* 2005;579:859-62.
11. Tsiropoulou G, Chatzipanagiotou S, Boufidou F, Kordinas V, Alevyzaki F, Zoga M, et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. *Am J Nephrol.* 2006;26:91-6.
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al., CKDEPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604-12.
13. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). *Nucleic Acids Res.* 1997;25:2595-7.
14. Frías C, García-Aranda C, de Juan C, Morán A, Ortega P, Gómez A, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. *Lung Cancer.* 2008;60:416-25.
15. Quimby JM, Maranon DG, Battaglia CL, McLeland SM, Brock WT, Bailey SM. Feline chronic kidney disease is associated with shortened telomeres and increased cellular senescence. *Am J Physiol Renal Physiol.* 2013;305:F295-303.
16. Rentoukas E, Tsarouhas K, Kaplanis I, Korou E, Nikolaou M, Marathonitis G, et al. Connection between telomerase activity in PBMC and markers of inflammation and endothelial dysfunction in patients with metabolic syndrome. *PLoS One.* 2012;7:e35739.
17. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. *Lancet.* 2005;366:662-4.
18. Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM, et al. Obesity and weight gain in adulthood and telomere length. *Cancer Epidemiol Biomark Prev.* 2009;18:816-20.
19. Lee M, Martin H, Firpo MA, Demerath EW. Inverse association between adiposity and telomere length: the Fels Longitudinal Study. *Am J Hum Biol.* 2011;23:100-6.
20. Lin Y, Damjanovic A, Metter EJ, Nguyen H, Truong T, Najjar K, et al. Age-associated telomere attrition of lymphocytes in vivo is coordinated with changes in telomerase activity, composition of lymphocyte subsets and health conditions. *Clin Sci (Lond).* 2015;128:367-77.
21. Zalli A, Carvalho LA, Lin J, Hamer M, Erusalimsky JD, Blackburn EH, et al. Shorter telomeres with high telomerase activity are associated with raised allostatic load and impoverished psychosocial resources. *Proc Natl Acad Sci U S A.* 2014;111:4519-24.
22. Epel ES, Lin J, Dhabhar FS, Wolkowitz OM, Puterman E, Karan L, et al. Dynamics of telomerase activity in response to acute psychological stress. *Brain Behav Immun.* 2010;24:531-9.
23. Roth A, Yssel H, Pene J, Chavez EA, Schertzer M, Lansdorp PM, et al. Telomerase levels control the lifespan of human T lymphocytes. *Blood.* 2003;102:849-57.
24. Gizard F, Heywood EB, Findeisen HM, Zhao Y, Jones KL, Cudejko C, et al. Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. *Arterioscler Thromb Vasc Biol.* 2011 Feb;31:245-52.
25. Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M, et al. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. *J Immunol Methods.* 2010;352:71-80.
26. Narducci ML, Grasselli A, Biasucci LM, Farsetti A, Mulè A, Liuzzo G, et al. High telomerase activity in neutrophils from unstable coronary plaques. *J Am Coll Cardiol.* 2007 Dec 18;50:2369-74.
27. Tsiropoulou G, Chatzipanagiotou S, Boufidou F, Kordinas V, Zoga M, Alevyzaki F, et al. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients. *Nephrology (Carlton).* 2006;11:506-9.
28. Boccardi V, Barbieri M, Rizzo MR, Marfella R, Esposito A, Marano L, et al. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. *FASEB J.* 2013;27:3879-85.